Synthetic Cationic Peptide IDR-1002 and Human Cathelicidin LL37 Modulate the Cell Innate Response but Differentially Impact PRRSV Replication
PRRSV
adjuvant
host defense peptides
poly(I:C)
porcine alveolar macrophages
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
02
2019
accepted:
27
06
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Host defense peptides (HDPs) show both antimicrobial and immunomodulatory properties making them important mediators of the host immune system. In humans but also in pigs many HDPs have been identified and important families such as cathelicidins and defensins have been established. In our study, we assessed: (i) the potential interactions that could occur between three peptides (LL37, PR39, and synthetic innate defense regulator (IDR)-1002) and a common TLR ligand called poly(I:C); (ii) the impact of selected peptides on the response of alveolar macrophage (AM) to poly(I:C) stimulation; (iii) the anti-porcine respiratory and reproductive syndrome virus (PRRSV) properties of the peptides; and (iv) their adjuvant potential in a PRRSV challenge experiment after immunization with different vaccine formulations. The results are as following: LL37, PR39, and IDR-1002 were able to interact with poly(I:C) using an agarose gel migration assay. Then, an alteration of AM's response to poly(I:C) stimulation was observed when the cells were co-stimulated with LL37 and IDR-1002. Regarding the anti-PRRSV potential of the peptides only LL37 showed a PRRSV inhibition in infected AM as well as precision cut lung slices (PCLS). However, in our conditions and despite their immunomodulatory properties, neither LL37 nor IDR-1002 showed any convincing potential as an adjuvant when associated to killed PRRSV in a challenge experiment. In conclusion, both antiviral and immunomodulatory properties could be identified for LL37, only immunomodulatory properties for IDR-1002, and both peptides failed to improve the immune response consecutive to an immunization with a killed vaccine in a PPRSV challenge experiment. However, further studies are needed to fully decipher and explain differences between peptide properties.
Identifiants
pubmed: 31355218
doi: 10.3389/fvets.2019.00233
pmc: PMC6640542
doi:
Types de publication
Journal Article
Langues
eng
Pagination
233Références
Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):187-94
pubmed: 10795591
Respir Res. 2000;1(3):141-50
pubmed: 11667978
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
J Immunol. 2002 Oct 1;169(7):3883-91
pubmed: 12244186
Virology. 2003 Apr 25;309(1):18-31
pubmed: 12726723
J Immunol. 2004 Feb 1;172(3):1763-7
pubmed: 14734759
Antimicrob Agents Chemother. 2005 May;49(5):1727-32
pubmed: 15855488
J Am Vet Med Assoc. 2005 May 15;226(10):1707-11
pubmed: 15906573
Curr Eye Res. 2005 May;30(5):385-94
pubmed: 16020269
Vet Res Commun. 2007 Jul;31(5):611-9
pubmed: 17252319
Curr HIV Res. 2007 Jul;5(4):410-5
pubmed: 17627504
Hum Vaccin. 2008 Jan-Feb;4(1):44-9
pubmed: 18438105
Dev Comp Immunol. 2009 Mar;33(3):334-43
pubmed: 18579204
Mol Immunol. 2009 Feb;46(5):927-36
pubmed: 19110312
Viral Immunol. 2009 Jul;22(4):235-42
pubmed: 19594394
Curr Drug Deliv. 2010 Jan;7(1):13-20
pubmed: 19863483
J Immunol. 2010 Mar 1;184(5):2539-50
pubmed: 20107187
Clin Vaccine Immunol. 2010 Apr;17(4):503-12
pubmed: 20130128
Eur J Immunol. 2010 Apr;40(4):1118-26
pubmed: 20140902
Vaccine. 2010 Aug 23;28(37):6006-13
pubmed: 20637306
Peptides. 2010 Nov;31(11):1966-72
pubmed: 20705109
Virus Res. 2010 Dec;154(1-2):1-6
pubmed: 20951175
Vaccine. 2010 Dec 6;28(52):8306-14
pubmed: 21036133
Vaccine. 2011 Feb 11;29(8):1595-604
pubmed: 21215343
J Immunol. 2011 May 1;186(9):5497-505
pubmed: 21441450
Vaccine. 2011 Sep 2;29(38):6540-8
pubmed: 21771625
Vaccine. 2011 Oct 13;29(44):7718-26
pubmed: 21856353
PLoS One. 2011;6(10):e25333
pubmed: 22031815
PLoS One. 2011;6(10):e26632
pubmed: 22039520
Vaccine. 1990 Aug;8(4):299-303
pubmed: 2204242
J Immunol. 2011 Dec 1;187(11):5653-9
pubmed: 22048772
J Leukoc Biol. 2012 Oct;92(4):735-42
pubmed: 22701042
Vaccine. 2012 Jul 27;30(35):5206-14
pubmed: 22713718
BMC Res Notes. 2012 Sep 28;5:539
pubmed: 23016650
Molecules. 2012 Oct 18;17(10):12276-86
pubmed: 23079498
J Biol Chem. 2013 Mar 22;288(12):8258-68
pubmed: 23386607
J Leukoc Biol. 2013 Jul;94(1):159-70
pubmed: 23616580
PLoS One. 2013 Aug 30;8(8):e73659
pubmed: 24023689
Future Microbiol. 2014;9(1):55-73
pubmed: 24328381
Vet Microbiol. 2014 Feb 21;169(1-2):18-32
pubmed: 24418046
Vet Res. 2014 Apr 09;45:42
pubmed: 24712747
PLoS One. 2014 Apr 22;9(4):e95939
pubmed: 24755622
Trends Immunol. 2014 Sep;35(9):443-50
pubmed: 25113635
Antivir Ther. 2015;20(6):573-82
pubmed: 25409681
Eur J Immunol. 2015 May;45(5):1402-13
pubmed: 25655317
ILAR J. 2015;56(1):53-62
pubmed: 25991698
Annu Rev Anim Biosci. 2016;4:129-54
pubmed: 26646630
J Immunol. 2016 Mar 15;196(6):2699-710
pubmed: 26873992
Front Cell Infect Microbiol. 2016 Dec 27;6:194
pubmed: 28083516
Peptides. 2017 Jun;92:23-30
pubmed: 28400226
FEMS Microbiol Rev. 2017 May 1;41(3):323-342
pubmed: 28521337
Vet Microbiol. 2017 May;204:133-140
pubmed: 28532792
Trends Microbiol. 2017 Dec;25(12):968-979
pubmed: 28652073
Peptides. 2017 Sep;95:76-83
pubmed: 28764966
Vaccines (Basel). 2018 Sep 14;6(3):null
pubmed: 30223448
Front Immunol. 2018 Oct 02;9:2299
pubmed: 30333837